Wockhardt sets issue price at Rs 225/share for Rs 748-cr rights issue

Earlier in January this year, Wockhardt's board had approved raising of up to Rs 1,000 crore through a rights issue to its existing shareholders

Wockhardt
Representative Picture.
Press Trust of India New Delhi
1 min read Last Updated : Mar 03 2022 | 7:20 PM IST

Pharmaceuticals firm Wockhardt Ltd on Thursday said it has fixed issue price at Rs 225 per share for its Rs 748-crore rights issue.

The capital raising committee of the company's board on Thursday decided to approve the issue of 3.33 crore fully paid-up equity shares, aggregating to a little over Rs 748 crore, Wockhardt said in a regulatory filing.

The issue price has been fixed at Rs 225 per fully paid-up equity share, including a premium of Rs 220 per share, it added.

The issue will open on March 15 and close on March 22, 2022.

Earlier in January this year, Wockhardt's board had approved raising of up to Rs 1,000 crore through a rights issue to its existing shareholders.

The objective of the issue is to meet financing needs of the company for repayment of subordinated debt, financing research and development initiatives and for general corporate purposes, it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Wockhardtpharmaceutical firmsIndian pharma companies

First Published: Mar 03 2022 | 7:20 PM IST

Next Story